Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials

Sodium-glucose transporters 2 inhibitors (SGLT-2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are recommended along with metformin for the potential cardiovascular benefits among type 2 diabetes. This meta-analysis aims to evaluate whether the effects of SGLT-2i or GLP-1 RAs on cardio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of medical research 2025-01, Vol.30 (1), p.13-17, Article 13
Hauptverfasser:	Zhang, Yuxin, Li, Zhaoji, Hao, Yongchen
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Cardiovascular disease Cardiovascular Diseases - drug therapy Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Dextrose Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy GLP-1 Ras Glucagon Glucagon-Like Peptide-1 Receptor - agonists Glucose Heart failure Humans Hypoglycemic agents Hypoglycemic Agents - therapeutic use Male Meta-analysis Metformin - therapeutic use Middle Aged Randomized Controlled Trials as Topic Review SGLT-2i Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!